We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

204 hedge funds and large institutions have $3.33B invested in Xenon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 86 increasing their positions, 51 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

69% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 51

59% more capital invested

Capital invested by funds: $2.1B → $3.33B (+$1.23B)

56% more funds holding in top 10

Funds holding in top 10: 9 → 14 (+5)

13% more funds holding

Funds holding: 180 → 204 (+24)

2.19% more ownership

Funds ownership: 95.63% → 97.83% (+2.2%)

4% less call options, than puts

Call options by funds: $39M | Put options by funds: $40.6M

Holders
204
Holders Change
+24
Holders Change %
+13.33%
% of All Funds
2.97%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
46
Increased
86
Reduced
51
Closed
19
Calls
$39M
Puts
$40.6M
Net Calls
-$1.6M
Net Calls Change
+$6.69M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$86M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$49.6M
3
BlackRock
BlackRock
New York
+$38M
4
FLAM
First Light Asset Management
Minnesota
+$36.9M
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$31.5M

Top Sellers

1
BI
BVF Inc
California
-$33.1M
2
NIP
Nicholas Investment Partners
California
-$27.1M
3
Marshall Wace
Marshall Wace
United Kingdom
-$22.1M
4
SC
Samlyn Capital
New York
-$18.7M
5
B
Braidwell
Connecticut
-$16.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
HS
101
HighVista Strategies
Massachusetts
$2.39M +$585K +16,546 +47%
AA
102
ALPS Advisors
Colorado
$2.34M +$121K +3,431 +7%
EAM
103
Erste Asset Management
Austria
$2.31M +$530K +15,000 +43%
Envestnet Asset Management
104
Envestnet Asset Management
Illinois
$2.08M +$39.8K +1,127 +3%
Tudor Investment Corp
105
Tudor Investment Corp
Connecticut
$1.99M +$1.53M +43,221 New
N
106
Nuveen
North Carolina
$1.86M -$47K -1,331 -3%
BFM
107
Boothbay Fund Management
New York
$1.85M +$1.42M +40,256 New
DekaBank Deutsche Girozentrale
108
DekaBank Deutsche Girozentrale
Germany
$1.8M +$671K +19,000 +95%
CIBC World Market
109
CIBC World Market
Ontario, Canada
$1.75M -$264K -7,480 -16%
Royal Bank of Canada
110
Royal Bank of Canada
Ontario, Canada
$1.66M +$316K +8,934 +33%
TA
111
TLS Advisors
Florida
$1.52M – – –
Renaissance Technologies
112
Renaissance Technologies
New York
$1.5M +$378K +10,700 +49%
PCM
113
Prelude Capital Management
New York
$1.48M +$581K +16,438 +104%
Aberdeen Group
114
Aberdeen Group
United Kingdom
$1.48M +$1.13M +32,036 New
UBS Group
115
UBS Group
Switzerland
$1.43M +$885K +25,061 +426%
Jane Street
116
Jane Street
New York
$1.35M +$174K +4,911 +20%
Simplex Trading
117
Simplex Trading
Illinois
$1.31M +$624K +17,652 +164%
LIP
118
Lighthouse Investment Partners
Florida
$1.28M +$981K +27,775 New
CCM
119
Cinctive Capital Management
New York
$1.27M +$975K +27,600 New
NSEDCP
120
NJ State Employees Deferred Compensation Plan
New Jersey
$1.15M – – –
JF
121
Jump Financial
Illinois
$1.11M +$848K +24,000 New
DMKJ
122
David M. Knott Jr
$1.1M – – –
RG
123
Rathbones Group
United Kingdom
$1.09M – – –
SMH
124
Sanders Morris Harris
Texas
$1.03M – – –
BG
125
Bellevue Group
Switzerland
$1.01M -$67.1K -1,900 -8%
3 4
5
6 7

XENE Hedge Fund Activity: Q4 2023 in Review

204 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2023, worth a combined $3.33B — up 59% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new XENE positions and 19 closed out — a net gain of 27 holders — while 86 added to existing stakes and 51 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $86M. The largest seller was BVF Inc, cutting an estimated $33.1M.

  • 204 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2023, up from 180 in Q3 2023.
  • Funds reported $3.33B of Xenon Pharmaceuticals stock for Q4 2023, up 59% quarter-over-quarter.
  • 46 funds opened new Xenon Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +27 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2023 was Wellington Management Group, an estimated $86M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2023 was BVF Inc, an estimated $33.1M sold.

Based on aggregated 13F filings for Q4 2023.